Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

Richard K. Burt*, Roumen Balabanov, Joachim Burman, Basil Sharrack, John A. Snowden, Maria Carolina Oliveira, Jan Fagius, John Rose, Flavia Nelson, Amilton Antunes Barreira, Kristina Carlson, Xiaoqiang Han, Daniela Moraes, Amy Morgan, Kathleen Quigley, Kimberly Yaung, Regan Buckley, Carri Alldredge, Allison Clendenan, Michelle A. CalvarioJacquelyn Henry, Borko Jovanovic, Irene B. Helenowski

*Corresponding author for this work

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Importance: Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS). Objective: To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression. Design, Setting, and Participants: Between September 20, 2005, and July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in the prior year, and an Expanded Disability Status Scale (EDSS; score range, 0-10 [10 = worst neurologic disability]) score of 2.0 to 6.0 were randomized at 4 US, European, and South American centers. Final follow-up occurred in January 2018 and database lock in February 2018. Interventions: Patients were randomized to receive HSCT along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of higher efficacy or a different class than DMT taken during the previous year (n = 55). Main Outcomes and Measures: The primary end point was disease progression, defined as an EDSS score increase after at least 1 year of 1.0 point or more (minimal clinically important difference, 0.5) on 2 evaluations 6 months apart, with differences in time to progression estimated as hazard ratios. Results: Among 110 randomized patients (73 [66%] women; mean age, 36 [SD, 8.6] years), 103 remained in the trial, with 98 evaluated at 1 year and 23 evaluated yearly for 5 years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months (interquartile range, 18-48 months) in the DMT group (hazard ratio, 0.07; 95% CI, 0.02-0.24; P <.001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (between-group mean difference, -1.7; 95% CI, -2.03 to -1.29; P <.001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events). Conclusions and Relevance: In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety. Trial Registration: ClinicalTrials.gov Identifier: NCT00273364.

Original languageEnglish (US)
Pages (from-to)165-174
Number of pages10
JournalJAMA - Journal of the American Medical Association
Volume321
Issue number2
DOIs
StatePublished - Jan 15 2019

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Hematopoietic Stem Cell Transplantation
Disease Progression
Randomized Controlled Trials
Group Psychotherapy
Therapeutics
Antilymphocyte Serum
Cyclophosphamide
Nervous System
Sepsis
Myocardial Infarction
Outcome Assessment (Health Care)
Databases
Safety
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Burt, Richard K. ; Balabanov, Roumen ; Burman, Joachim ; Sharrack, Basil ; Snowden, John A. ; Oliveira, Maria Carolina ; Fagius, Jan ; Rose, John ; Nelson, Flavia ; Barreira, Amilton Antunes ; Carlson, Kristina ; Han, Xiaoqiang ; Moraes, Daniela ; Morgan, Amy ; Quigley, Kathleen ; Yaung, Kimberly ; Buckley, Regan ; Alldredge, Carri ; Clendenan, Allison ; Calvario, Michelle A. ; Henry, Jacquelyn ; Jovanovic, Borko ; Helenowski, Irene B. / Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis : A Randomized Clinical Trial. In: JAMA - Journal of the American Medical Association. 2019 ; Vol. 321, No. 2. pp. 165-174.
@article{e78bd3efce0a4d888e5efab9388ba7f2,
title = "Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial",
abstract = "Importance: Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS). Objective: To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression. Design, Setting, and Participants: Between September 20, 2005, and July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in the prior year, and an Expanded Disability Status Scale (EDSS; score range, 0-10 [10 = worst neurologic disability]) score of 2.0 to 6.0 were randomized at 4 US, European, and South American centers. Final follow-up occurred in January 2018 and database lock in February 2018. Interventions: Patients were randomized to receive HSCT along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of higher efficacy or a different class than DMT taken during the previous year (n = 55). Main Outcomes and Measures: The primary end point was disease progression, defined as an EDSS score increase after at least 1 year of 1.0 point or more (minimal clinically important difference, 0.5) on 2 evaluations 6 months apart, with differences in time to progression estimated as hazard ratios. Results: Among 110 randomized patients (73 [66{\%}] women; mean age, 36 [SD, 8.6] years), 103 remained in the trial, with 98 evaluated at 1 year and 23 evaluated yearly for 5 years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months (interquartile range, 18-48 months) in the DMT group (hazard ratio, 0.07; 95{\%} CI, 0.02-0.24; P <.001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (between-group mean difference, -1.7; 95{\%} CI, -2.03 to -1.29; P <.001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events). Conclusions and Relevance: In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety. Trial Registration: ClinicalTrials.gov Identifier: NCT00273364.",
author = "Burt, {Richard K.} and Roumen Balabanov and Joachim Burman and Basil Sharrack and Snowden, {John A.} and Oliveira, {Maria Carolina} and Jan Fagius and John Rose and Flavia Nelson and Barreira, {Amilton Antunes} and Kristina Carlson and Xiaoqiang Han and Daniela Moraes and Amy Morgan and Kathleen Quigley and Kimberly Yaung and Regan Buckley and Carri Alldredge and Allison Clendenan and Calvario, {Michelle A.} and Jacquelyn Henry and Borko Jovanovic and Helenowski, {Irene B.}",
year = "2019",
month = "1",
day = "15",
doi = "10.1001/jama.2018.18743",
language = "English (US)",
volume = "321",
pages = "165--174",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "2",

}

Burt, RK, Balabanov, R, Burman, J, Sharrack, B, Snowden, JA, Oliveira, MC, Fagius, J, Rose, J, Nelson, F, Barreira, AA, Carlson, K, Han, X, Moraes, D, Morgan, A, Quigley, K, Yaung, K, Buckley, R, Alldredge, C, Clendenan, A, Calvario, MA, Henry, J, Jovanovic, B & Helenowski, IB 2019, 'Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial', JAMA - Journal of the American Medical Association, vol. 321, no. 2, pp. 165-174. https://doi.org/10.1001/jama.2018.18743

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis : A Randomized Clinical Trial. / Burt, Richard K.; Balabanov, Roumen; Burman, Joachim; Sharrack, Basil; Snowden, John A.; Oliveira, Maria Carolina; Fagius, Jan; Rose, John; Nelson, Flavia; Barreira, Amilton Antunes; Carlson, Kristina; Han, Xiaoqiang; Moraes, Daniela; Morgan, Amy; Quigley, Kathleen; Yaung, Kimberly; Buckley, Regan; Alldredge, Carri; Clendenan, Allison; Calvario, Michelle A.; Henry, Jacquelyn; Jovanovic, Borko; Helenowski, Irene B.

In: JAMA - Journal of the American Medical Association, Vol. 321, No. 2, 15.01.2019, p. 165-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis

T2 - A Randomized Clinical Trial

AU - Burt, Richard K.

AU - Balabanov, Roumen

AU - Burman, Joachim

AU - Sharrack, Basil

AU - Snowden, John A.

AU - Oliveira, Maria Carolina

AU - Fagius, Jan

AU - Rose, John

AU - Nelson, Flavia

AU - Barreira, Amilton Antunes

AU - Carlson, Kristina

AU - Han, Xiaoqiang

AU - Moraes, Daniela

AU - Morgan, Amy

AU - Quigley, Kathleen

AU - Yaung, Kimberly

AU - Buckley, Regan

AU - Alldredge, Carri

AU - Clendenan, Allison

AU - Calvario, Michelle A.

AU - Henry, Jacquelyn

AU - Jovanovic, Borko

AU - Helenowski, Irene B.

PY - 2019/1/15

Y1 - 2019/1/15

N2 - Importance: Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS). Objective: To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression. Design, Setting, and Participants: Between September 20, 2005, and July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in the prior year, and an Expanded Disability Status Scale (EDSS; score range, 0-10 [10 = worst neurologic disability]) score of 2.0 to 6.0 were randomized at 4 US, European, and South American centers. Final follow-up occurred in January 2018 and database lock in February 2018. Interventions: Patients were randomized to receive HSCT along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of higher efficacy or a different class than DMT taken during the previous year (n = 55). Main Outcomes and Measures: The primary end point was disease progression, defined as an EDSS score increase after at least 1 year of 1.0 point or more (minimal clinically important difference, 0.5) on 2 evaluations 6 months apart, with differences in time to progression estimated as hazard ratios. Results: Among 110 randomized patients (73 [66%] women; mean age, 36 [SD, 8.6] years), 103 remained in the trial, with 98 evaluated at 1 year and 23 evaluated yearly for 5 years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months (interquartile range, 18-48 months) in the DMT group (hazard ratio, 0.07; 95% CI, 0.02-0.24; P <.001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (between-group mean difference, -1.7; 95% CI, -2.03 to -1.29; P <.001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events). Conclusions and Relevance: In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety. Trial Registration: ClinicalTrials.gov Identifier: NCT00273364.

AB - Importance: Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS). Objective: To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression. Design, Setting, and Participants: Between September 20, 2005, and July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in the prior year, and an Expanded Disability Status Scale (EDSS; score range, 0-10 [10 = worst neurologic disability]) score of 2.0 to 6.0 were randomized at 4 US, European, and South American centers. Final follow-up occurred in January 2018 and database lock in February 2018. Interventions: Patients were randomized to receive HSCT along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of higher efficacy or a different class than DMT taken during the previous year (n = 55). Main Outcomes and Measures: The primary end point was disease progression, defined as an EDSS score increase after at least 1 year of 1.0 point or more (minimal clinically important difference, 0.5) on 2 evaluations 6 months apart, with differences in time to progression estimated as hazard ratios. Results: Among 110 randomized patients (73 [66%] women; mean age, 36 [SD, 8.6] years), 103 remained in the trial, with 98 evaluated at 1 year and 23 evaluated yearly for 5 years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months (interquartile range, 18-48 months) in the DMT group (hazard ratio, 0.07; 95% CI, 0.02-0.24; P <.001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (between-group mean difference, -1.7; 95% CI, -2.03 to -1.29; P <.001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events). Conclusions and Relevance: In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety. Trial Registration: ClinicalTrials.gov Identifier: NCT00273364.

UR - http://www.scopus.com/inward/record.url?scp=85059932603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059932603&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.18743

DO - 10.1001/jama.2018.18743

M3 - Article

C2 - 30644983

AN - SCOPUS:85059932603

VL - 321

SP - 165

EP - 174

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 2

ER -